Less than 10% of U.S. stroke patients get a treatment that evidence shows is most effective for a certain type of stroke, and the odds are even lower for patients who are black and Hispanic.
Surgeons are no better at determining which patients might benefit from operations to treat torn knee cartilage than if they just flipped a coin, a new study suggests.
The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.
Researchers at Rutgers University-New Brunswick recently published research about a nanotechnology platform that helps identify what happens to specific stem cells.
Regeneron Pharmaceuticals announced positive results from the company’s pivotal Phase III clinical trial of evinacumab in homozygous familial hypercholesterolemia (HoFH).
Eli Lilly announced that the company’s psoriasis drug Taltz overcame Johnson & Johnson’s Tremfya in a head-to-head study.
Published research shows promise in using Sanofi’s multiple sclerosis drug Aubagio in addition to targeted cancer therapy to treat the aggressive brain cancer glioblastoma.
Regeneron Pharmaceuticals Inc. said the company’s experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death.
AstraZeneca Plc said a late-stage study showed the company’s top-selling drug Tagrisso had significantly helped patients with a type of lung cancer live longer without the disease worsening.
Drugmaker Eli Lilly and Company said early results from a study suggest that Apple Inc. devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer’s disease dementia and those without symptoms.
